Difference between revisions of "Venous thromboembolism - null regimens"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| − | ! style="width: | + | !style="width: 20%"|Study |
| − | ! style="width: | + | !style="width: 20%"|Dates of enrollment |
| − | ! style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| − | ! style="width: | + | !style="width: 20%"|Comparator |
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://doi.org/10.1016/s2352-3026(23)00314-9 O'Brien et al. 2023 (PREVAPIX-ALL)] | |[https://doi.org/10.1016/s2352-3026(23)00314-9 O'Brien et al. 2023 (PREVAPIX-ALL)] | ||
| + | |2015-10-22 to 2021-06-04 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Apixaban_monotherapy|Apixaban]] | |[[Venous_thromboembolism#Apixaban_monotherapy|Apixaban]] | ||
| Line 31: | Line 33: | ||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| − | ! style="width: | + | !style="width: 20%"|Study |
| − | ! style="width: | + | !style="width: 20%"|Dates of enrollment |
| − | ! style="width: | + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] |
| − | ! style="width: | + | !style="width: 20%"|Comparator |
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
|[https://doi.org/10.1016/s0140-6736(96)91009-0 Gärdlund et al. 1996] | |[https://doi.org/10.1016/s0140-6736(96)91009-0 Gärdlund et al. 1996] | ||
| + | |1988-1991 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Heparin_monotherapy|UFH]]; SC | |[[Venous_thromboembolism#Heparin_monotherapy|UFH]]; SC | ||
| Line 42: | Line 46: | ||
|- | |- | ||
|[https://doi.org/10.7326/0003-4819-153-1-201007060-00004 Hull et al. 2010 (EXCLAIM)] | |[https://doi.org/10.7326/0003-4819-153-1-201007060-00004 Hull et al. 2010 (EXCLAIM)] | ||
| + | |2002-02 to 2006-03 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | |[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | ||
| Line 47: | Line 52: | ||
|- | |- | ||
|[https://doi.org/10.1056/NEJMoa1111288 Kakkar et al. 2011 (LIFENOX)] | |[https://doi.org/10.1056/NEJMoa1111288 Kakkar et al. 2011 (LIFENOX)] | ||
| + | |2008-01 to 2010-09 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | |[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | ||
| Line 52: | Line 58: | ||
|- | |- | ||
|[https://doi.org/10.1056/NEJMoa1805090 Spyropoulos et al. 2018 (MARINER)] | |[https://doi.org/10.1056/NEJMoa1805090 Spyropoulos et al. 2018 (MARINER)] | ||
| + | |2014-06 to 2018-01 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Rivaroxaban_monotherapy|Rivaroxaban]] | |[[Venous_thromboembolism#Rivaroxaban_monotherapy|Rivaroxaban]] | ||
| Line 57: | Line 64: | ||
|- | |- | ||
|[https://doi.org/10.1056/NEJMoa1814630 Khorana et al. 2019 (CASSINI)] | |[https://doi.org/10.1056/NEJMoa1814630 Khorana et al. 2019 (CASSINI)] | ||
| + | |NR | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Rivaroxaban_monotherapy|Rivaroxaban]] | |[[Venous_thromboembolism#Rivaroxaban_monotherapy|Rivaroxaban]] | ||
| Line 62: | Line 70: | ||
|- | |- | ||
|[https://doi.org/10.1056/EVIDoa2200332 Mottier et al. 2023 (SYMPTOMS)] | |[https://doi.org/10.1056/EVIDoa2200332 Mottier et al. 2023 (SYMPTOMS)] | ||
| + | |2015-09 to 2020-09 | ||
| style="background-color:#1a9851" |Phase 3 (C) | | style="background-color:#1a9851" |Phase 3 (C) | ||
|[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | |[[Venous_thromboembolism#Enoxaparin_monotherapy|Enoxaparin]] | ||
Revision as of 23:51, 29 June 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main VTE page for regimens that include active treatment.
VTE primary prophylaxis
Observation
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| O'Brien et al. 2023 (PREVAPIX-ALL) | 2015-10-22 to 2021-06-04 | Phase 3 (C) | Apixaban | Did not meet primary endpoint of composite of symptomatic or clinically unsuspected venous thromboembolism |
No treatment.
References
- PREVAPIX-ALL: O'Brien SH, Rodriguez V, Lew G, Newburger JW, Schultz CL, Orgel E, Derr K, Ranalli MA, Esbenshade AJ, Hochberg J, Kang HJ, Dinikina Y, Mills D, Donovan M, Dyme JL, Favatella NA, Mitchell LG; PREVAPIX-ALL investigators. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Jan;11(1):e27-e37. Epub 2023 Nov 16. link to original article PubMed NCT02369653
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Gärdlund et al. 1996 | 1988-1991 | Phase 3 (C) | UFH; SC | Did not meet primary endpoint of necropsy-verified pulmonary embolism of predefined clinical relevance |
| Hull et al. 2010 (EXCLAIM) | 2002-02 to 2006-03 | Phase 3 (C) | Enoxaparin | Inferior composite VTE rate |
| Kakkar et al. 2011 (LIFENOX) | 2008-01 to 2010-09 | Phase 3 (C) | Enoxaparin | Did not meet primary endpoint of death rate at 30 days |
| Spyropoulos et al. 2018 (MARINER) | 2014-06 to 2018-01 | Phase 3 (C) | Rivaroxaban | Did not meet primary endpoint of symptomatic VTE or death due to VTE |
| Khorana et al. 2019 (CASSINI) | NR | Phase 3 (C) | Rivaroxaban | Did not meet primary endpoint of objectively confirmed proximal DVT in a lower limb, PE, symptomatic DVT in an upper limb or distal DVT in a lower limb, and death from VTE up to 180 days |
| Mottier et al. 2023 (SYMPTOMS) | 2015-09 to 2020-09 | Phase 3 (C) | Enoxaparin | Did not meet primary endpoint of symptomatic VTE at 30 days |
No active treatment.
References
- Gärdlund B; Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet. 1996 May 18;347(9012):1357-61. link to original article PubMed
- EXCLAIM: Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. link to original article PubMed NCT00077753
- LIFENOX: Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. link to original article PubMed NCT00622648
- MARINER: Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. Epub 2018 Aug 26. link to original article PubMed NCT02111564
- CASSINI: Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720-728. link to original article PubMed NCT02555878
- SYMPTOMS: Mottier D, Girard P, Couturaud F, Lacut K, Le Moigne E, Paleiron N, Guellec D, Sanchez O, Cogulet V, Laporte S, Marhic G, Mismetti P, Presles E, Robert-Ebadi H, Mahé I, Plaisance L, Reny JL, Darbellay Farhoumand P, Cuvelier C, Le Henaff C, Lambert Y, Danguy Des Deserts M, Rousseau Legrand C, Boutreux S, Bleher Y, Decours R, Trinh-Duc A, Armengol G, Benhamou Y, Daumas A, Guyot SL, De Carvalho H, Lamia B, Righini M, Meyer G, Le Gal G. Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients. NEJM Evidence. NEJM Evid. 2023 Aug;2(8):EVIDoa2200332. Epub 2023 Jun 27. link to original article PubMed NCT02379806